Odisha Pharma Summit 2025 to Explore Opportunities in Pharmaceutical Sector on December 16

The Odisha government is set to host the Odisha Pharma Summit 2025 on December 16. This event aims to unite stakeholders from the pharmaceutical and medical devices industries to explore new opportunities. Chief Minister Mohan Charan Majhi will inaugurate the programme. An official mentioned that the state will introduce the Odisha Pharmaceutical and Medical Devices Policy 2025 during this event.

The new policy is designed to attract investments, enhance business ease, and generate large-scale employment in the life sciences sector. Additionally, the government plans to announce the development of a Pharmaceutical Park and a Medical Devices Park. These initiatives aim to bolster the state’s healthcare manufacturing infrastructure and promote industry growth.

Focus on Industry Growth
Industries Minister Sampad Chandra Swain stated, “Odisha welcomes all pharma, medical devices & related sector industries, investors, and thought leaders to join us at this summit. We are committed to building a strong, future-ready ecosystem that supports growth, innovation, and global competitiveness.” The summit will also feature the signing of MoUs between the government and leading companies.

This collaboration marks a significant step towards enhancing the state’s pharmaceutical and medical devices ecosystem. The government encourages healthcare and industry enthusiasts to participate in this initiative, which aims to shape the future of the sector in Odisha.

The event’s agenda includes discussions on investment opportunities and strategies for improving business operations in the life sciences field. By bringing together industry leaders and investors, Odisha aims to position itself as a hub for pharmaceutical and medical device manufacturing.

Related Posts

AbbVie loses patent plea for Hep C drug

New Delhi: The Indian Patent Office has refused to grant a secondary patent to AbbVie for its blockbuster Hepatitis C drug combination glecaprevir/pibrentasvir, sold globally under the brand name Maviret.…

GSK’s Calpol a well-known trademark: High Court

New Delhi: In a relief to UK-headquartered GlaxoSmithKline Pharmaceuticals (GSK), the Delhi High Court has declared its pain and fever medicine ‘Calpol’ as a well-known trademark that has acquired extensive…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

AbbVie loses patent plea for Hep C drug

AbbVie loses patent plea for Hep C drug

GSK’s Calpol a well-known trademark: High Court

GSK’s Calpol a well-known trademark: High Court

3 arrested for allegedly posing as doctors using forged MBBS degrees

3 arrested for allegedly posing as doctors using forged MBBS degrees

Commissioner FDA reviews enforcement measures

Commissioner FDA reviews enforcement measures

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer